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Abstract Two major distinct subsets of dendritic cells
(DCs) are arranged to regulate our immune responses in
vivo; 33D1+ and DEC-205+ DCs. Using anti-33D1-speciWc
monoclonal antibody, 33D1+ DCs were successfully
depleted from C57BL/6 mice. When 33D1+ DC-depleted
mice were stimulated with LPS, serum IL-12, but not IL-10
secretion that may be mediated by the remaining DEC-205+
DCs was markedly enhanced, which may induce Th1 dom-
inancy upon TLR signaling. The 33D1+ DC-depleted mice,
implanted with syngeneic Hepa1-6 hepatoma or B16-F10
melanoma cells into the dermis, showed apparent inhibition
of already established tumor growth in vivo when they
were subcutaneously (sc) injected once or twice with LPS
after tumor implantation. Moreover, the development of
lung metastasis of B16-F10 melanoma cells injected intra-
venously was also suppressed when 33D1+ DC-deleted
mice were stimulated twice with LPS in a similar manner,
in which the actual cell number of NK1.1+CD3¡ NK cells
in lung tissues was markedly increased. Furthermore, intra-
peritoneal (ip) administration of a very small amount of
melphalan (L-phenylalanine mustard; L-PAM) (0.25 mg/kg)
in LPS-stimulated 33D1+ DC-deleted mice helped to
induce H-2Kb-restricted epitope-speciWc CD8+ cytotoxic T
lymphocytes (CTLs) among tumor-inWltrating lymphocytes
against already established syngeneic E.G7-OVA lym-
phoma. These Wndings indicate the importance and eVec-
tiveness of selective targeting of a speciWc subset of DCs,
such as DEC-205+ DCs alone or with a very small amount
of anticancer drugs to activate both CD8+ CTLs and NK
eVectors without externally added tumor antigen stimula-
tion in vivo and provide a new direction for tumor immuno-
therapy.
Keywords 33D1 · DEC-205 · DC · Innate immunity · 
Acquired immunity · CTL
Introduction
Tumor cells develop from normal cells through several
genetic transformation steps. Thus, transformed tumor cells
express characteristic cell antigens that may activate vari-
ous tumor-speciWc immune eVectors. Among those eVec-
tors, CD8+ cytotoxic T lymphocytes (CTLs), which
speciWcally recognize tumor-derived peptide epitopes pre-
sented on their surface in association with class I MHC
molecule are the most potent eVectors and such tumor epi-
tope-speciWc CD8+ CTLs can be primed in vivo by immu-
nization with epitope peptide-pulsed syngeneic dendritic
cells (DCs) [1].
However, tumor-derived-speciWc epitope peptides are
generally very diYcult to determine for most tumors that
express either mutated or non-mutated tumor-associated
antigens (TAA) containing CTL epitopes. TAA captured by
antigen-presenting cells (APCs), such as macrophages or
DCs, are generally processed into peptide fragments in
acidic endosomes and presented them in conjunction with
class II MHC molecules that can stimulate CD4+ helper T
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lymphocytes (Th), but not CD8+ CTLs restricted by class I
MHC [2]. Nevertheless, in some situations, most suitable
CTL epitopes within antigenic proteins such as TAA are
selected to present in conjunction with class I MHC even
when the externally added antigenic proteins are captured
by APCs. This phenomenon is called “cross-presentation”
[3, 4]. So far, we have shown that cross-presentation can be
induced when antigenic proteins are administered with a
speciWc adjuvant, such as ISCOMs [5] or with TLR3 ligand
poly(I:C) [6]. The key cells to generate such cross-presenta-
tion are DCs. Recently, it has been demonstrated that two
major distinct subsets of DCs are arranged to regulate our
immune responses in vivo; 33D1+ and DEC-205+ DCs [7].
More recently, it has been reported that in vivo targeting of
DEC-205 with either poly(I:C) [8] or an antibody speciWc
for DC-NK lectin group receptor-1 (DNGR-1) [9] induced
dominant Th1 immunity or potent CTL responses via cross-
presentation, respectively. Moreover, DCs have been found
to directly activate tumor-speciWc NK cells in the innate
arm of the immune system [10]. These results suggest that
selective stimulation of DEC-205+ DCs in vivo may elicit
eVective acquired CD8+ CTL responses through Th1 domi-
nancy and trigger innate NK cells, by both of which protec-
tive immunity against implanted tumors will be achieved
even in the absence of externally added tumor antigens.
In the present study, we attempted to deplete 33D1+
DCs in vivo to establish DEC-205+ DC dominancy by
inoculation with anti-33D1-speciWc monoclonal anti-
body (mAb), and DEC-205+ DC-dominant mice were
successfully obtained in which 33D1+ DCs were com-
pletely eliminated for at least several weeks. To our sur-
prise, based on our recent Wndings [11], when 33D1+
DC-depleted mice were injected twice with LPS at
weekly intervals, 100 g on day 3 and 50 g on day 10
after syngeneic Hepa1-6 hepatoma or B16-F10 mela-
noma implantation, apparent inhibition of already estab-
lished tumor growth, probably mediated through IL-12
secretion from the remaining DEC-205+ DCs, was
observed in vivo, although no tumor-derived substances
were co-administrated. Moreover, lung metastasis of
B16-F10 melanoma in 33D1+ DC-depleted mice seemed
to be suppressed mainly by NK cells that might also be
activated by IL-12 secreted via LPS stimulation. Fur-
thermore, intraperitoneal (ip) administration of a small
amount of melphalan (L-phenylalanine mustard; L-PAM)
(0.25 mg/kg) in LPS-stimulated 33D1+ DC-deleted mice
helped to induce H-2Kb-restricted epitope-speciWc CD8+
CTLs among tumor-inWltrating lymphocytes (TILs)
against already established syngeneic E.G7-OVA lym-
phoma. These Wndings suggest that selective stimulation
of innate DEC-205+ DCs in vivo may assist in generat-
ing eVective acquired epitope-speciWc class I MHC mol-
ecule-restricted conventional CD8+ CTLs or NK cells
against already established tumors without externally
added tumor antigen stimulation when they are slightly
attacked in vivo with a very small amount of anticancer
drugs, such as L-PAM.
Materials and methods
Mice
Six- to 7-week-old female C57BL/6 (H-2b) mice were pur-
chased from Charles River Japan (Kanagawa, Japan), main-
tained in micro-isolator cages under speciWc pathogen-free
conditions and fed autoclaved laboratory chow and water.
All animal experiments were performed according to the
guidelines for the care and use of laboratory animals set by
the National Institutes of Health (NIH; MD) and approved
by the Review Board of Nippon Medical School (Tokyo,
Japan).
Syngeneic tumors
As for syngeneic tumors, Hepa1-6 (hepatoma, H-2b), B16-
F10 (melanoma, H-2b) and E.G7-OVA (thymoma, H-2b)
cells were obtained from American Type Culture Collec-
tion (ATCC). B16-OVA (melanoma, H-2b) cells were
kindly gifted by Prof. Lieping Chen, Johns Hopkins
University School of Medicine.
In vivo depletion of 33D1+ DCs, CD8+ T cells, or NK cells
Culture supernatants of 33D1 or 3.155 hybridoma cells
(ATCC, VA, USA) were collected and 33D1 mAb against
DC inhibitory receptor-2 (DCIR2) or 3.155 mAb (rat IgM)
against mouse CD8 was puriWed from the supernatant by
ion-exchange chromatography using diethylaminoethyl
(DEAE) cellulose (DE52; Whatman, Maidstone, UK) as
previously described [12]. For in vivo depletion of 33D1+
DCs, mice were intraperitoneally (ip) injected with 0.5 mg
puriWed 33D1 mAb or control rat IgG (Jackson Immuno
Research Laboratories, PA) for three consecutive days and
boosted with 0.5 mg of the same IgG 14 days after the Wrst
injection. For in vivo depletion of CD8+ T cells, mice were
ip injected with 0.5 mg anti-CD8 mAb (3.155) or control
rat IgM (Rockland, PA) for three consecutive days and
boosted with 0.5 mg of the same IgM 14 days after the Wrst
injection.
For in vivo depletion of NK cells, mice were intrave-
nously (iv) injected with 20 l anti-asialo GM1 Ab
(Wako Pure Chemical Industries, Osaka, Japan) or con-
trol rabbit serum diluted to 300 l with PBS for three
consecutive days and boosted with the same antiserum
once a week.Cancer Immunol Immunother (2010) 59:1083–1095 1085
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Preparation of intraepithelial (IE) cells, spleen (SP) cells, 
lung cells and TILs, as well as enrichment 
of DC or lymphocyte population
IE cells, SP cells, lung cells and TILs were prepared by the
method described previously [11]. To prepare IE cells, after
the small intestine was obtained from a mouse, fecal mate-
rials were Xushed from the lumen with HBSS (Invitrogen
Life Technologies, CA) and connective tissues were care-
fully removed. The obtained intestine was inverted and cut
into several segments that were transferred to a 50 ml coni-
cal tube (Becton Dickinson Labware, NJ) containing 45 ml
HBSS with 5% FCS, 100 U/ml penicillin (Invitrogen Life
Technologies) and 100 g/ml streptomycin (Invitrogen Life
Technologies). The tube was then shaken at 37°C for
45 min (horizontal position; orbital shaker at 150 rpm).
Harvested cells from the intestinal epithelium were passed
through an 80-mm nylon mesh to remove tissue debris. To
prepare SP cells, lung cells, and TILs, the spleen, lung, or
tumor was aseptically removed and cut into small frag-
ments. The tissue fragments were incubated in 1 mg/ml col-
lagenase D (Roche, Basel, Switzerland) at 37°C for 45 min
and crushed gently. The obtained cells were washed and
passed through nylon mesh.
DC populations were enriched from IE cells, SP cells
and lung cells as described previously [13, 14] and a lym-
phocyte fraction including NK cells was also obtained from
a cell suspension of lung or tumor by the method described
previously [11]. To enrich DCs, the obtained cells were
suspended in 10 ml of 30% (1.045 g/ml) Percoll solution
(Amersham Biosciences, Uppsala, Sweden) overlaid on
2 ml of 60% (1.075 g/ml) Percoll solution. The solution
was centrifuged at 950g for 20 min and DCs were recov-
ered at the interphase between 30 and 60% Percoll solu-
tions. To collect the fraction including lymphocytes and
NK cells, cells from the lung or tumor were suspended in
10 ml of 30% Percoll solution and centrifuged at 1,800 rpm
(620g) for 20 min. Cells at the bottom were re-suspended in
10 ml of 40% Percoll solution overlaid on 2 ml of 70% Per-
coll solution. The solution was centrifuged at 1,800 rpm for
20 min and lymphocytes and NK cells were recovered at
the interphase of 40 and 70% Percoll solutions. The col-
lected cells were suspended in complete T cell medium [15]
composed of RPMI 1640 medium (Sigma-Aldrich,
St. Louis, MO) supplemented with 2 mM L-glutamine (MP
Biomedicals), 1 mM sodium pyruvate (Invitrogen Life
Technologies), 0.1 mM nonessential amino acid (Invitro-
gen Life Technologies), a mixture of vitamins (MP Bio-
medicals), 1 mM HEPES (Invitrogen Life Technologies),
100 U/ml penicillin (Invitrogen Life Technologies),
100 g/ml streptomycin (Invitrogen Life Technologies),
50 mM 2-ME (Sigma-Aldrich) and heat-inactivated 10%
FCS.
In vivo stimulation with either LPS or poly(I:C)
Mice were anaesthetized and subcutaneously (sc) injected
with 100 g LPS (Sigma-Aldrich) or poly(I:C) (Sigma-
Aldrich) once for the cytokine assay as described previ-
ously [6]. Tumor-bearing mice were anaesthetized and sc
injected with 100 g LPS once and then boosted with 50 g
LPS 7 days after the Wrst injection of LPS.
Measurement of cytokine production
Peripheral blood was collected from anaesthetized mice
using heparinized capillary tubes before and 2, 6 and 8 h
after LPS injection. The blood was centrifuged for 10 min
at 6,000g, and plasma was collected and frozen at ¡80°C
until assay. IL-12-p40 and IL-10 levels in plasma samples
were measured using speciWc ELISA kits (BioSource Inter-
national, CA) as described previously [6].
In vivo neutralization of IL-12
For in vivo neutralization of IL-12, mice were ip injected
with 100 g anti-mouse IL-12 Ab (R&D Systems, MN) or
control goat IgG (Jackson Immuno Research Laboratories)
just before injection of LPS at 3 and 10 days after tumor
implantation.
Flow cytometry analysis
BrieXy, 1–5 £ 105 cells were pre-incubated with mAb
against the Fc gamma receptor (FcgRII/III; 2.4G2) to block
FcR-mediated binding, and then double-stained with FITC-
conjugated mAb and PE-conjugated mAb. The following
mAbs were purchased from BD Biosciences (San Diego,
CA); PE-conjugated 33D1, FITC or PE-conjugated CD11c
(N418), FITC-conjugated CD3 (145-2C11), PE-conju-
gated NK1.1 (PK136), PE-conjugated CD4 (RM4-5) and
FITC or PE-conjugated CD8 (53–6.7). FITC-conjugated
CD8 (CT-CD8) and DEC-205 (NLDC-145) were
purchased from Caltag Laboratories (Burlingame, CA)
and Cedarlane (ON, Canada), respectively. PE-conjugated
H-2Kb/OVA tetramers-SIINFEKL [16] for the detection of
OVA-speciWc CTLs was purchased from Beckman Coulter
(Fullerton, CA). Dead cells were determined using propi-
dium iodide (PI; Sigma-Aldrich) or 7-amino-actinomycin
D viability dye (Beckman Coulter), and stained cells were
analyzed with FACScan using the CellQuest program (BD
Biosciences).
Measurement of in vivo antitumor eVects
For in vivo antitumor experiments, C57BL/6 mice were
anesthetized and syngeneic Hepa 1–6 (5 £ 106), B16-F101086 Cancer Immunol Immunother (2010) 59:1083–1095
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(1 £ 106), B16-OVA (5 £ 105) ,  o r  E . G 7 - O V A  ( 5£ 106)
tumor cells in 100 l PBS were injected intracutaneously
(ic) into abdominal dermal tissue. For tumor metastasis
experiments, B16-F10 cells (1 £ 105) in 250 l PBS were
injected into the tail vein of C57BL/6 mice. The growing
tumors implanted into dermal tissues were followed by
measuring the length (a) and width (b) and the tumor vol-
ume (V) was calculated according to the formula V = ab2/2,
as previously reported [11, 17]. Mice were anesthetized and
killed according to the guidelines for the care and use of
laboratory animals when the longer axis of each tumor was
over 20 mm or the calculated volume was over 4,000 mm3.
To assess pulmonary metastasis, the lungs were removed
from mice 14 days after the injection of B16-F10 cells.
Metastasis foci of the lung were counted and lung weight
was measured.
Chemotherapy
A fresh stock solution of 10 mg melphalan (L-PAM) (Wako
Pure Chemical Industries, Osaka, Japan) per milliliter was
prepared just prior to injection, as previously described
[18], and was further diluted with Dulbecco’s phosphate-
buVered saline, pH 7.2. As a very low non-aVected dose
[19], 0.25 mg L-PAM per kg was administered ip 10 days
after implantation of E.G7-OVA to mice.
CTL assay
Freshly isolated SP cells and TILs were used for the
CTL assay and cytolytic activity was measured using a
standard 51Cr-release assay as previously described [15].
In brief, various numbers of eVector cells were incu-
bated with 5 £ 103 51Cr-labeled targets for 4 h at 37°C
in 200 l RPMI 1640 medium containing 10% FCS in
round-bottom 96-well cell culture plates (BD Biosci-
ences). After incubation, the plates were centrifuged for
10 min at 330g, and 100 l cell-free supernatants were
collected to measure radioactivity with a Packard Auto-
Gamma 5650 counter (Hewlett-Packard Japan). Maxi-
mum release was determined from the supernatant
of cells that had been lysed by the addition of 5% Triton
X-100, and spontaneous release was determined from
target cells incubated without added eVector cells. The
percentage of speciWc lysis was calculated as 100(exper-
imental release ¡ spontaneous release)/(maximum release ¡
spontaneous release).
Statistical analysis
Student’s t test was used to determine the statistical signiW-
cance of diVerences between groups. Data were considered
signiWcant at P < 0.05.
Results
Distribution of 33D1- or DEC-205+ DCs in the spleen 
and IE of normal C57BL/6 mice
Based on recent Wndings [7] that there are two major dis-
tinct subsets of DCs controlling antigen presentation in
vivo, we Wrst attempted to determine the tissue distribution
of 33D1- or DEC-205+ DCs in both systemic lymphoid
organs, such as the spleen, and local surface tissues, such as
IE of the small intestine, in normal C57BL/6 mice. DCs are
usually identiWed as CD11c+ cells by Xow cytometry analy-
sis. Among CD11c+ cells, nearly an equal number of 33D1+
DCs (6.1%) and DEC-205+ DCs (8.4%) were observed in
the spleen, while a lower percentage of DEC-205+ cells
(1.2%) in comparison with 33D1+ DCs (5.2%) could be
seen among intraepithelial cells (IECs) (Fig. 1a, upper pan-
els). It is important to note that, similar to a recent report by
Dudziak et al. [7], CD11c+ DCs expressing both 33D1 and
DEC-205 molecules could not be detected. The results sug-
gest that 33D1+ DCs are equally distributed in both sys-
temic and local tissues, whereas DEC-205+ DCs are
predominantly arranged in systemic compartments rather
than local intraepithelia. Many malignant carcinomas origi-
nate from various epithelial tissues, where 33D1+ DCs are
dominantly arranged; therefore, 33D1+ DCs in surface epi-
thelial compartments must be involved in local immunolog-
ical surveillance to achieve antitumor immunity. Thus, we
attempted to examine the eVect of depletion of the 33D1+
DC subset in vivo on challenged tumor growth based on a
recently established procedure [11].
In vivo depletion of 33D1+ DCs by ip injection 
of anti-33D1 mAb
We then tried to deplete the 33D1+ DC subset in vivo by ip
injection of anti-33D1 mAb in mice. When anti-33D1 Ab
(0.5 mg per day) was injected ip for three consecutive days,
33D1+CD11c+ DCs were successfully depleted in both
spleen cells and IECs 1 day after the Wnal inoculation,
while no change in the number of DEC-205+ DCs was
observed in both the spleen and IE (Fig. 1a, lower panels).
To determine the continuation of the eVect mediated by
the injection of anti-33D1 mAb, we measured the number
of 33D1+CD11c+ DCs weekly for three successive weeks.
Although 33D1+CD11c+ DCs were completely deleted
until 2 weeks after the injection of anti-33D1 mAb, they
recovered at 3 weeks in both spleen cells (1.7%) and IECs
(4.6%) (Fig. 1b). Accordingly, the mice were boosted once
by an additional ip injection of anti-33D1 mAb (0.5 mg per
day) 2 weeks after the initial injection; 1 and 2 weeks after
this boost, 33D1+ DCs had completely disappeared in both
the spleen and intra-epithelia (Fig. 1b), indicating thatCancer Immunol Immunother (2010) 59:1083–1095 1087
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successful eradication of the 33D1+ DC subset is achiev-
able until at least 4 weeks after the initial inoculation of
anti-33D1 mAb using the prime-boost procedure indicated
above. In contrast, when the control rat IgG in the same iso-
type as 33D1 was ip injected into mice, the number of both
33D1+ and DEC-205+ DCs remained unchanged (data not
shown).
SigniWcant enhancement of IL-12 secretion 
in 33D1+ DC-depleted mice
We established 33D1+ DC-deWcient mice, in which DEC-
205+ DCs are predominantly distributed. A recent report
indicated that such DEC-205+ DCs induced a large number
of Th1 type CD4+ T cells through Toll-like receptor (TLR)
signaling if DEC-205+ DCs were stimulated by poly(I:C)
[8]. Thus, we examined the ability to produce cytokines in
the sera of 33D1+ DC-depleted mice when they were stimu-
lated by a TLR ligand, such as LPS for TLR4 or poly(I:C)
for TLR3 based on the procedure described previously [6]
since most of the remaining CD11c+ DCs were CD80- and
CD86-negative immature DCs (data not shown). Serum IL-
12 production, which may shift the Th1/Th2 balance into
the Th1 predominant state, was signiWcantly enhanced in
33D1+ DC-depleted mice (P < 0.05) 2, 6 and 8 h after
single sc injection with 100 g LPS, the ligand for TLR4,
when compared with control mice treated with rat IgG,
whereas an injection of 100 g poly(I:C), the ligand for
TLR3, showed weaker secretion of IL-12 than LPS stimula-
tion in our 33D1+ DC-depleted mice (Fig. 2). In addition,
serum IL-10 production was almost identical to stimulation
with LPS between 33D1+ DC-depleted mice and control
untreated mice, but serum IL-10 could not be detected
when poly(I:C) was injected into those mice (Fig. 2). These
results indicate that in vivo depletion of 33D1+ DCs can
cause signiWcant enhancement of IL-12, but not IL-10 pro-
duction by stimulation with LPS, which may induce Th1
dominancy upon TLR signaling.
Suppression of implanted tumor growth at the dermis 
in 33D1+ DC-depleted mice with LPS stimulation
To examine the in vivo eVects of Th1 dominancy on antitu-
mor immunity, 33D1+ DC-depleted C57BL/6 mice, in
which such Th1 dominancy can be achieved via LPS stimu-
lation, each mouse was implanted with a 5 £ 106 syngeneic
Hepa1-6 hepatoma cell line into the dermis and simulta-
neously injected sc once with 100 g LPS. The growth of
implanted Hepa1-6 was signiWcantly suppressed when
compared with control rat IgG-treated mice, although there
Fig. 1 a Distribution of 33D1- or DEC-205+ DCs in the spleen as well
as in the intestinal epithelium of normal and anti-33D1 mAb injected
C57BL/6 mice. To determine the distribution of 33D1- or DEC-205+
DCs, normal C57BL/6 mice were killed and analyzed by Xow cytom-
etry. Distributions of the indicated DC-subtypes either in the spleen
(SP) (left six panels) or in the intestinal epithelium (IE) (right six
panels) are shown. Among these panels, the upper six panels were
obtained from untreated and the lower six panels were from anti-33D1
mAb ip injected C57BL/6 mice. b Kinetics for in vivo depletion of
33D1+ DCs by ip injection of anti-33D1 mAb. To determine the con-
tinuation of the eVect by anti-33D1 mAb treatment, C57BL/6 mice
were killed and the percentage of remaining 33D1+ DCs either in the
SP (upper six panels) or in the IE (lower six panels) was measured by
Xow cytometry every week for three successive weeks after anti-33D1
mAb ip injection. To achieve complete elimination of 33D1+ DCs,
single additional ip injection of anti-33D1 mAb was performed
2 weeks after the initial administration, and their eVect was examined
for at least another 2 weeks (right four panels)
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was no diVerence between groups without LPS stimulation
(Fig. 3a).
Moreover, based on our recent Wndings [11], when
33D1+ DC-depleted mice were injected sc twice with LPS
at weekly intervals, 100 g on day 3 and 50 g on day 10
after syngeneic tumor implantation, apparent inhibition of
already established B16-F10 growth in vivo was observed
(Fig. 3b), which may have been caused by tumor-inWltrat-
ing CD8+ T lymphocytes seen in tissue specimens (data not
shown).
To determine whether secreted IL-12 is critical for tumor
regression in 33D1+ DC-depleted mice, 100 g anti-mouse
IL-12 Ab or control goat IgG was ip injected just after LPS
stimulation on day 3 and 10 days after B16-F10 tumor
implantation. When mice were treated with control goat
IgG, tumor growth was still signiWcantly suppressed
(Fig. 3c; upper panel), in which serum IL-12 secretion at 2
and 6 h after LPS stimulation was enhanced when com-
pared with mice treated with control rat IgG (Fig. 3d; upper
panel). In contrast, tumor growth suppression in 33D1+
DC-depleted mice was totally abrogated (Fig. 3c; lower
panel) when serum IL-12 was neutralized by an injection of
anti-mouse IL-12 Ab just before LPS stimulation (Fig. 3d;
lower panel).
Furthermore, to conWrm whether CD8+ T cells are criti-
cal in the suppression of implanted tumor growth in 33D1+
DC-depleted mice, CD8+ T cells were depleted in vivo and
tumor growth of B16-F10 was pursued (Fig. 3e, f). As indi-
cated in Fig. 3e (lower panel), suppression of tumor growth
was abrogated in 33D1+ DC-depleted mice when CD8+ T
cells were depleted in vivo by injection of anti-mouse CD8
mAb (3.155) (Fig. 3f). These results suggest that in vivo
production of IL-12 in 33D1+ DC-depleted mice via LPS
stimulation might be required to suppress tumor growth in
the dermis by tumor-inWltrating CD8+ T cells.
Suppression of lung metastasis of B16-F10 melanoma 
in 33D1+ DC-depleted mice stimulated with LPS
As shown in Fig. 3b, we observed marked suppression of
B16-F10 melanoma growth implanted into the dermis.
Thus, we attempted to determine whether the development
of B16-F10 lung metastasis could be suppressed in 33D1+
DC-depleted mice when stimulated with LPS. 33D1+ DC-
depleted C57BL/6 mice were injected intravenously (iv)
with 1 £ 105 B16-F10 melanoma suspended with 0.25 ml
PBS(¡) via the tail vein per mouse and then stimulated
twice with LPS at weekly intervals, 100 g at day 3 and
50 g at day 10 after syngeneic tumor implantation. Four-
teen days after the injection of B16-F10 melanoma, the
number of lung metastases in each mouse was counted. The
number of lung metastasis in 33D1+ DC-depleted, LPS-
treated mice was apparently reduced in comparison with
control mice treated with rat IgG or LPS alone visually
(Fig. 4a) as well as numerically (Fig. 4b). This was con-
Wrmed by signiWcant reduction in the total volume of the
lung in 33D1+ DC-depleted, LPS-treated mice (P <0 . 0 1 ;
Fig. 4c). These results clearly demonstrate that not only
growth of the tumor implanted into the dermis, but also the
development of lung metastasis could be suppressed in
33D1+ DC-depleted mice when they were stimulated with
LPS.
Suppression of lung metastasis of B16-F10 melanoma 
cells by NK cells
To determine the cells involved in the suppression of lung
metastasis by LPS stimulation in 33D1+ DC-depleted mice,
lymphocyte subsets obtained from lung tissues with B16-
F10 melanoma metastasis were analyzed by Xow cytome-
try. Importantly, the percentage of NK1.1+CD3¡ NK cells
in the lung tissues of LPS-stimulated 33D1+ DC-deleted
mice, in which metastasis development was apparently sup-
pressed, were markedly increased when compared with the
untreated control (P = 0.058) or isotype-matched rat-
IgG-treated mice (Fig. 5a, b). In addition, there was no
diVerence in the percentage of CD8+ T cells in lung tissues
Fig. 2 SigniWcant enhancement of IL-12 secretion in 33D1+ DC-de-
pleted mice. To examine the ability to secrete cytokines in the sera of
33D1+ DC-depleted mice (Wlled bars), they were sc administrated once
either with 100 g LPS, the ligand for TLR4, or with 100 g poly(I:C),
the ligand for TLR3 and the amount of two representative cytokines,
IL-10 and IL-12, was measured by ELISA at 2, 6 and 8 h after stimu-
lation. Upper panels show the amounts of IL-12 and lower panels
IL-10 after single sc injection of LPS (left two panels) or poly(I:C)
(right two panels). Open bars indicate the sera from control mice
injected with isotype-matched mAb (rat IgG). Asterisk (*) indicates
statistically signiWcant diVerences (P < 0.05) between 33D1+ DC-
depleted and control rat-IgG-treated groups
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bearing metastasis between rat-IgG-treated and 33D1-
treated mice (Fig. 5b).
To conWrm whether NK cells are important in the sup-
pression of B16-F10 tumor metastasis, NK cells were
depleted in vivo by anti-asialo GM1 Ab treatment. Mice
were iv injected with anti-asialo GM1 Ab for NK cell
depletion or control rabbit serum and ip injected with 33D1
mAb or control rat IgG before iv injection of B16-F10
Fig. 3 Suppression of tumor growth implanted into the dermis of
33D1+ DC-depleted mice with LPS stimulation and eVect of blocking
on IL-12 secretion and depletion of CD8+ T cells for suppression. a
5 £ 106 syngeneic Hepa1-6 hepatoma cells were injected into the der-
mis of 33D1+ DC-depleted (Wlled circle) or control isotype-matched
rat-IgG-treated (open circle) C57BL/6 mice. Based on the Wndings in
Fig. 2, 100 g LPS was injected sc together with the implantation of
Hepa1-6 cells (right panel). b, c, e 1 £ 106 syngeneic B16-F10 mela-
noma cells were injected into the dermis of 33D1+ DC-depleted (closed
circle) or control rat-IgG-treated (open circle) C57BL/6 mice, which
were injected twice with LPS at weekly intervals, 100 g on day 3 and
50 g on day 10 after tumor implantation. Asterisk (*) indicates statis-
tically signiWcant diVerences (P < 0.05) between 33D1+ DC-depleted
and control rat-IgG-treated groups on the same day. Mice were also
treated with anti-mouse IL-12-speciWc Ab or control goat IgG just
before LPS injection on day 3 and 10 for in vivo neutralization of
IL-12 (c) or anti-mouse CD8 Ab (3.155) or control rat IgM at days 7,
6 and 5 before and day 7 after tumor injection for in vivo depletion of
CD8+ T cells (e). d Sera were collected from 33D1 + DC-depleted
(Wlled bars) or control mice (open bars) 2 and 6 h after LPS stimulation
following ip injection with anti-mouse IL-12 Ab or goat IgG, and
IL-12 p40 in the sera was measured by ELISA. f CD4+ and CD8+ lym-
phocytes in the spleen from mice 7 days after injection with anti-CD8
Ab or rat IgM were analyzed by Xow cytometry
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melanoma, and then stimulated with LPS as described
above. To our surprise, B16-F10 metastasis in the lungs of
NK cell-depleted mice seriously progressed visually
(Fig. 5c) and the weight of their lungs markedly increased
(Fig. 5d) regardless of 33D1+ DC depletion when compared
with metastasis in control mice without NK cell depletion.
In the lung of 33D1+ DC-depleted mice treated with control
rabbit serum, in which B16-F10 metastasis was apparently
suppressed (Fig. 5c, d), the percentage of NK1.1+CD3¡ NK
cells (Fig. 5e) and their NK activity against YAC-1 target
cells (Fig. 5f) were markedly enhanced. In addition, it
should be noted that some NK1.1+CD3+ NKT cells were
observed in the metastatic lung (Fig. 5e), although the
actual function of those NKT cells remains to be eluci-
dated.
Thus, lung metastasis seems to be suppressed by NK
cells that might be activated also via IL-12. Collectively, in
33D1+ DC-deleted mice, upon stimulation with LPS, the
remaining DEC-205+ DCs may secrete IL-12, by which
tumor-speciWc CD8+ CTLs and NK cells are activated with-
out co-administration of tumor antigens, and the former
activated CTLs seems to inhibit the implanted tumor
growth and the latter activated NK cells may suppress
tumor metastasis.
Induction of H-2Kb-restricted epitope-speciWc CD8+ CTLs 
among TILs in 33D1+ DC-depleted mice stimulated 
with LPS
To determine whether the cells involved in tumor regres-
sion are class I MHC molecule-restricted epitope-speciWc
conventional CD8+ CTLs in this system, we conducted
similar experiments using syngeneic B16-OVA melanoma
cells expressing the known CTL epitope (SIINFEKL) pre-
sented by Kb class I MHC molecules. Control mice or
33D1+ DC-deleted mice were sc implanted with B16-OVA
melanoma and ip injected with LPS twice as described
above. The growth of implanted B16-OVA melanoma
33D1+ DC-depleted mice was signiWcantly (P < 0.05) sup-
pressed in comparison with control rat-IgG-treated mice
(Fig. 6a). It should be noted that H-Kb/OVA tetramer-posi-
tive cells apparently increased among freshly isolated CD8+
TILs from 33D1+ DC-deleted mice, although tetramer-pos-
itive cells were not seen in the spleens of the same mice
(Fig. 6b; left panel). In addition, the percentage of
NK1.1+CD3- NK cells as well as NK1.1+CD3+ NKT cells
was increased in TILs from 33D1+ DC-deleted mice
(Fig. 6b; right panel).
These results suggest that selective stimulation of innate
DEC-205+ DCs by 33D1+ DC depletion and LPS injection
might eVectively induce not only tumor antigen-speciWc
CD8+ T cells, but also NK and NKT cells in tumor tissues,
which suppress tumor growth in the dermis.
IP co-administration of a very low dose of L-PAM 
with LPS helped to induce H-2Kb-restricted 
epitope-speciWc CD8+ CTLs among TILs 
against E.G7-OVA tumor
The previous Wndings obtained using B16-OVA (Fig. 6a, b)
suggest that selective stimulation of innate DEC-205+ DCs
in vivo may assist to generate eVective acquired epitope-
speciWc class I MHC molecule-restricted conventional
CD8+ CTLs against already established tumors without
externally added tumor antigen stimulation. To conWrm this
observation, we used another syngeneic tumor cells, E.G7-
OVA thymoma, expressing the same CTL epitope
(SIINFEKL) presented by Kb class I MHC molecules as
B16-OVA.
In comparison with other syngenic tumors, such as
Hepa1-6, B16-F10 and B16-OVA, the regression of
implanted E.G7-OVA in 33D1+ DC-deleted mice was
almost unchanged by two injections of LPS. Nevertheless,
ip inoculation of L-PAM at a very low dose (0.25 mg/kg)
10 days after implanting E.G7-OVA in a mouse resulted in
marked reduction in the implanted EG7-OVA (Fig. 6c;
P < 0.05). It should be noted that H-2Kb/OVA tetramer-
positive cells apparently increased among freshly isolated
Fig. 4 Suppression of lung metastasis of B16-F10 melanoma in
33D1+ DC-depleted mice stimulated with LPS. 33D1+ DC-depleted
C57BL/6 mice were injected iv with 1 £ 105 B16-F10 melanoma cells
via the tail vein per mouse and then stimulated twice with LPS at week-
ly intervals, 100 g on day 3 and 50 g on day 10 after syngeneic
tumor injection. Fourteen days after iv injection of B16-F10
melanoma, the number of lung metastases in each mouse was counted
either visually (a) or numerically (b). Total volume of the lung in
33D1+ DC-depleted, LPS-treated mice was signiWcantly reduced
(P < 0.01) (c)
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Fig. 5 EVect of number of NK cells on lung metastasis development.
a, b To determine the cells involved in the suppression of tumor metas-
tasis, lymphocyte subsets obtained from lung tissues with B16-F10
metastasis were analyzed by Xow cytometry. The percentage of
NK1.1+CD3- NK cells in the lung tissues of untreated mice and LPS-
stimulated 33D1+ DC-deleted mice was determined by Xow cytometry
analysis (a). The results are shown as the mean of the percentage §
SEM from 3 to 4 mice (b). Asterisk (*) indicates statistical diVerences
(P = 0.058) between the 33D1+ DC-depleted group and untreated
group. c–f EVect of depletion of NK cells in vivo by anti-asialo GM1-
speciWc Ab. NK cell-depleted mice were injected iv with 1 £ 105 B16-
F10 melanoma cells and stimulated twice with LPS at weekly intervals,
100 g on day 3 and 50 g on day 10 after tumor injection. Fourteen
days after iv injection of B16-F10 melanoma, lung (c) and SP were
removed from the mice and the weight of each lung was measured (d).
Asterisk (*) indicates statistically signiWcant diVerences (P <0 . 0 5 )
between the control group treated with both rabbit serum with rat IgG
and each treated group. Percentages of NK1.1+CD3¡ cells (e) and NK
activity (f) in the lung and SP cells were analyzed by Xow cytometry
and 51Cr-release assay using YAC-1 cells as targets. The results are
shown as the mean § SEM of triplicates from pooled lung or SP cells
obtained from 3 to 4 mice. The eVector: target (E:T) ratio is 100:1 or
80:1 in spleen or lung cells, respectively (f)
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CD8+ TILs from 33D1+ DC-deleted mice treated with
L-PAM, although the tetramer-positive cells were not seen
in the spleen of the same mice (Fig. 6d). Moreover, freshly
isolated such tetramer-positive CD8+ lymphocytes showed
marked epitope-speciWc cytotoxic activities (Fig. 6e), while
slight epitope-speciWc cytotoxic activities were observed in
other controls (Fig. 6e). This may be caused by two sc
injections with LPS because no cytotoxicity could be
Fig. 6 Suppression of B16-OVA tumor growth implanted into the
dermis and inWltration of OVA-speciWc CTLs into the tumor in 33D1+
DC-depleted mice. 5 £ 105 syngeneic B16-OVA melanoma cells were
injected into the dermis of 33D1+ DC-depleted or control isotype-
matched rat-IgG-treated C57BL/6 mice, which were injected twice
with LPS at weekly intervals, 100 g on day 3 and 50 g on day 10
after tumor implantation. Tumor growth (a) of 33D1+ DC-depleted
mice was signiWcantly suppressed (P < 0.05) on day 14 after tumor
implantation, compared with mice treated with control rat IgG. To
determine the cells involved in the suppression of B16-OVA mela-
noma implanted into the dermis, lymphocyte subsets were obtained
from SP and tumor on day 14. These SP cells and TILs were stained
with PE-labeled H-2 Kb/OVA tetramer and FITC-labeled anti-CD8 or
PE-labeled anti-NK1.1 and FITC-labeled anti-CD3, and analyzed by
Xow cytometry (b). c, d, e EVect of additional L-PAM (non-toxic dose)
injection on the enhancement of epitope-speciWc CTL induction.
5 £ 106 syngeneic E.G7-OVA thymoma cells were injected into the
dermis of 33D1+ DC-depleted or control isotype-matched rat-IgG-
treated C57BL/6 mice, which were injected twice with LPS at weekly
intervals, 100 g on day 3 and 50 g on day 10 after tumor implanta-
tion. L-PAM (0.25 mg/kg) was ip injected some of these mice at day 10
after the tumor implantation. Tumor growth (c) of mice treated with
both 33D1 and L-PAM was signiWcantly suppressed (P < 0.05) on day
13 after tumor implantation (3 days after L-PAM treatment), compared
with mice treated with control rat IgG. To determine cells involved in
the suppression of E.G7-OVA tumor implanted into the dermis, lym-
phocyte subsets were obtained from SP and tumor on day 13. These SP
cells and TILs were stained with PE-labeled H-2Kb/OVA tetramer and
FITC-labeled anti-CD8 and analyzed by Xow cytometry (d). OVA-
speciWc CTL and NK activity of SP cells and TILs were measured by
a 51Cr-release assay using E.G7-OVA, YAC-1 and EL4 cells pulsed
with or without OVA peptide as targets (e). The E:T ratio was 36:1 in
TILs or 100:1, 50:1 and 25:1 in SP cells
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detected in freshly isolated TILs from untreated mice (data
not shown). Furthermore, TILs from 33D1+ DC-deleted
mice, treated with L-PAM or not, showed similar NK cyto-
toxicity, from which the diVerence in E.G7-OVA tumor
growth between the two groups should not be mediated
(Fig. 6c, e). These Wndings suggest that selective stimula-
tion of innate DEC-205+ DCs may generate acquired epi-
tope-speciWc class I MHC molecule-restricted conventional
CD8+ CTLs against already established tumors when they
are slightly attacked in vivo with a very small amount of
anticancer drugs, such as L-PAM.
We then tried to conWrm the eVect of L-PAM treatment
on the induction of epitope-speciWc CD8+ CTLs using B16-
OVA. However, because B16-OVA was far more resistant
to anticancer drugs such as L-PAM than E.G7-OVA, we
needed more than 20 mg/kg to see a similar suppressive
eVect as has required for E.G7-OVA shown in Fig. 6c (light
gray bar and black bar on day 13) and such a high amount
of L-PAM treatment caused profound damage to the experi-
mental mice, from which we could not obtain suYcient
number of lymphocytes to analyze epitope speciWcity (data
not shown).
Nevertheless, the fact that epitope-speciWc CD8+ CTLs
for B16-OVA were seen in TILs from LPS-stimulated
33D1+ DC-deleted mice (Fig. 6b) strongly suggest that the
strategy for selective stimulation of innate DEC-205+ DCs
seems to provide a better way for controlling those cancer
drug-resistant tumors.
Discussion
Recent reports indicate that two major distinct DC subsets
control antigen presentation in vivo in mice [7]; 33D1- and
DEC-205+ DC. In the present study, we determined the tissue
distribution of these DCs using each-speciWc mAb and found
that 33D1+ DCs are seemingly equally distributed in both
systemic and local tissues, while DEC-205+ DCs are pre-
dominantly arranged in systemic compartments rather than
local intraepithelium of the small intestine in C56BL/6 mice.
Further studies are required to understand the reason for such
unbalanced tissue distribution of two distinct DC subsets,
particularly in the local surface area where numerous patho-
gens will be encountered externally and various carcinomas
will be produced internally. From our observation, more
DEC-205+ DCs are arranged in the spleen than in the intraep-
ithelial compartment. Indeed, compatible with our Wndings, it
has recently been reported that CD11c+DEC-205+ DCs were
abundant in the white pulp of the human spleen [20].
Using anti-33D1-speciWc mAb, we have successfully
established 33D1+ DC-deWcient mice, in which DEC-205+
DCs are predominantly distributed. Trumpfheller et al.
have recently reported that DEC-205+ DCs induce a large
number of Th1 type CD4+ T cells through TLR signaling if
DEC-205+ DCs are stimulated by poly(I:C) [8]. On the
basis of their Wndings, we injected 33D1+ DC-depleted
mice to stimulate the remaining DEC-205+ DCs either with
LPS (ligand for TLR4) or poly(I:C) (ligand for TLR3) [6].
Unexpectedly, higher in vivo production of IL-12, but not
IL-10 was induced in 33D1+ DC-depleted mice when they
were stimulated with LPS rather than with poly(I:C)
(Fig. 2). To eliminate the possibility that other batches of
poly(I:C) may have a more potent eVect on 33D1+ DC-
depleted mice for IL-12 production, we are currently testing
various lots of poly(I:C) to conWrm the discrepancy, which
may be generated by internal unbalanced DC dominancy
caused by the depletion of 33D1+ DCs.
Moreover, based on our recent Wndings [11], we injected
33D1+ DC-depleted mice twice with LPS at weekly inter-
vals, 100 g on day 3 and 50 g on day 10 after tumor
implantation and observed the apparent inhibition of
already established B16-F10 growth in vivo (Fig. 3b),
which may have been caused by tumor-inWltrating CD8+ T
lymphocytes seen in tissue specimens. These results sug-
gest that in vivo production of IL-12 in 33D1+ DC-depleted
mice via LPS stimulation might induce internal Th1 domi-
nancy, which may activate CD8+ tumor-speciWc CTLs and
induce the suppression of implanted tumor growth in the
dermis. In general, such activated CD8+ CTLs may recog-
nize either mutated or non-mutated TAA that often contain
speciWc CTL epitopes in conjunction with MHC class I
molecules and eliminate tumors in the implanted region
[21].
In contrast, the percentage of NK1.1+CD3- NK cells in
the lung tissues of LPS-stimulated 33D1+ DC-deleted mice,
in which metastasis development was apparently sup-
pressed, were markedly increased although the inWltration
of CD8+ T cells was not observed. These results indicate
that lung metastasis of B16-F10 melanoma seems to be
mainly suppressed by NK cells that might also be activated
by IL-12 secreted via LPS stimulation. Indeed, it has been
reported that metastasis was greatly enhanced by NK cell
depletion in DC-activated mice [22] and we have conWrmed
the above Wndings by NK cell depletion experiments
(Fig. 5). On the basis of our Wndings, we are currently
investigating the diVerence in class I MHC molecule
expression between the original tumor and tumors obtained
from the metastatic region. Taken together, upon the stimu-
lation of 33D1+ DC-deleted mice with LPS, the remaining
DEC-205+ DCs may secrete IL-12, by which both CD8+
CTLs and NK cells are activated without co-administration
of tumor antigens, and the former activated CTLs seems to
inhibit implanted tumor growth and the latter activated NK
cells may suppress tumor metastasis.
Our Wndings suggest that the stimulation of DEC-205+
DCs with a TLR ligand, such as LPS, in vivo is suYcient to1094 Cancer Immunol Immunother (2010) 59:1083–1095
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activate both tumor antigen-speciWc CD8+ CTLs at the
tumor implanted site and NK cells in metastatic regions at
the same time even in the absence of externally added
tumor antigens. Activated DEC-205+ DCs may take up
tumor antigens from tumor cells and cross-present tumor-
derived epitopes in association with class I MHC molecules
of their own to prime epitope-speciWc CD8+ CTLs in vivo
that can attack already established tumors. Although the
precise mechanism remains to be investigated, such selec-
tively stimulated DEC-205+ DCs appear also to activate
NK cells that prevent tumor metastasis. Indeed, very
recently, Sancho et al. [9] reported the usefulness of target-
ing DEC-205+ DCs with DNGR-1.
We have not conWrmed the actual eVector cells involved
in the regression of the implanted tumors such as Hepa1-6
hepatoma and B16-F10 melanoma cells, on which down-
modulated class I MHC molecules are sometimes
expressed, and thus they might be targets for activated NK
cells. Therefore, in order to conWrm whether the cells
involved in tumor regression are actually class I MHC mol-
ecule-restricted epitope-speciWc conventional CD8+ CTLs
in this system, we conducted similar experiments using
syngeneic E.G7-OVA and B16-OVA tumor cells that
should be eliminated by CD8+ CTLs recognizing the
known CTL epitope (SIINFEKL) presented by Kb class I
MHC molecules rather than by NK cells. In comparison
with other syngeneic tumors, the regression of implanted
E.G7-OVA in 33D1+ DC-deleted mice was almost
unchanged by two injections of LPS. Nevertheless, ip inoc-
ulation of a mouse with L-PAM at a very low unaVected
dose 10 days after implantation of E.G7-OVA resulted in
marked reduction of the implanted EG7-OVA. In regressed
tumors, we have observed an increased number of CD8+
H-2 Kb/OVA tetramer-positive cells showing marked epi-
tope-speciWc cytotoxic activities. These results indicate that
selective stimulation of DEC-205+ DCs in vivo may gener-
ate acquired epitope-speciWc class I MHC molecule-
restricted conventional CD8+ CTLs against already estab-
lished tumors, such as E.G7-OVA expressing class I MHC
when they are slightly attacked with a very small amount of
anticancer drugs, such as L-PAM. However, as shown with
B16-OVA, selective stimulation of innate DEC-205+ DCs
appears superior for controlling cancer drug-resistant
tumors instead of a high dose of anticancer drugs.
Taken together, the Wndings of the present study sug-
gest the importance and eVectiveness of selective target-
ing of a speciWc subset of innate DCs, such as DEC-205+
DCs, together with very small doses of anticancer drugs
against established tumors to activate functional acquired
MHC-I-associated eVectors, such as both CD8+ CTLs and
NK cells in vivo without co-administration of tumor epi-
tope antigens and provide a new direction for tumor
immunotherapy.
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